Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial

Abstract Background The pivotal ASPECT-NP trial showed ceftolozane/tazobactam was non-inferior to meropenem for the treatment of ventilated hospital-acquired/ventilator-associated bacterial pneumonia (vHABP/VABP). Here, we evaluated treatment outcomes by degree of respiratory or cardiovascular dysfu...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Ignacio Martin-Loeches, Andrew F. Shorr, Richard G. Wunderink, Marin H. Kollef, Jean-François Timsit, Brian Yu, Jennifer A. Huntington, Erin Jensen, Christopher J. Bruno
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Elsevier 2023-02-01
Rangatū:	Annals of Intensive Care
Ngā marau:	ASPECT-NP Gram-negative Nosocomial Pneumonia Pseudomonas Shock
Urunga tuihono:	https://doi.org/10.1186/s13613-022-01084-8
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!